AI is rapidly shifting the competitive landscape in biopharma, redefining how organizations generate insights, allocate resources, and outperform competitors. Insights & Analytics (I&A) and market research functions are under increasing expectations to deliver not just analysis, but decision advantage. However, for many companies, AI adoption remains constrained by data readiness, governance complexity, and gaps in operational integration.
This report examines how leading biopharma organizations are translating AI ambition into new SOPs, capabilities, and measurably improved performance. This critical report identifies where AI is driving the greatest business impact within biopharma market research, how top teams scale adoption responsibly, and which operating model shifts enable sustained value creation. This research provides executives with benchmarks and strategic clarity to ensure AI investments strengthen decision quality, accelerate market performance, increase efficiency, and build durable competitive edge.